Akili Interactive Labs, which developed the first prescription-only video-game-based platform to be cleared for marketing by the US Food and Drug Administration, announced on 26 January it plans to go public through a merger with Social Capital Suvretta Holdings Corp I., a special purpose acquisition company (SPAC) led by Chamath Palihapitiya as CEO.
The merger values the combined company at about $1bn and will provide Akili with up to $412m in gross cash proceeds, the companies said. The proceeds consist of the $250m the blank-check company raised in its initial public offering and $162m from private investment in public equity investors at $10 a share, of which $100m is from Social Capital
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?